Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe United Kingdom Cost Effectiveness

England’s Innovative Medicines Fund: Opportunities & Risks

  • News

Executive Summary

England’s Innovative Medicines Fund could make the UK a more attractive launch market following Brexit, but companies must also consider the risks of the fund.

You may also be interested in...



England Launches Innovative Medicines Fund

The new financing mechanism promises faster access to new treatments, but some industry concerns remain unresolved.

Brazilian Regulator Extends COVID-19 Measures

Brazil’s medicines regulator is extending COVID-19 era resolutions designed to speed up its evaluation of clinical research in Brazil.

Canada Publishes Real World Evidence Guidance For HTA And Regulatory Decision Making

The new guidance was drawn up through extensive engagement with national and international experts in RWD and RWE, as well as stakeholders in Canada.

Table

View full table

Topics

Tags:
Europe United Kingdom Cost Effectiveness
Latest Headlines

US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month

Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings

Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits

FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals

See All
UsernamePublicRestriction

Register

PS146487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By